This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of Toronto directory, so their publications, courses and email address may be missing. Find their university profile.
Latest funding
- $4,475,254
Androgen Suppression Combined with Elective Nodal and a Dose Escalated Boost. A Non-Inferiority, Phase 3 Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT)
CIHR · 2022 · Nominated PI
- $1,637,100
'Two-Step Authentication' for Optimal Prostate Cancer Risk Determination: An "Extracellular Vesicle"-Based Liquid Biopsy Followed by Multi-Parametric MRI.
CIHR · 2022 · Co-investigator
Androgen Suppression Combined with Elective Nodal and a Dose Escalated Boost. A Non-Inferiority, Phase 3 Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost (ASCENDE-SBRT)
Principal investigators: Loblaw, Douglas Andrew B
Keywords: Progression-Free Survival; Prostate Cancer; Radiotherapy; Randomized Controlled Trial; Tolerability
'Two-Step Authentication' for Optimal Prostate Cancer Risk Determination: An "Extracellular Vesicle"-Based Liquid Biopsy Followed by Multi-Parametric MRI.
Principal investigators: Leong, Hon Sing; Lim, Christopher
Keywords: "Liquid Biopsy"; Benign Prostatic Hyperplasia; Extracellular Vesicles; Gleason Group Score; Multi-Parametric Magnetic Resonance; Pi-Rads V2; Prostate Cancer; Prostate Needle Biopsy; Radiology; Risk Stratification
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.